Quest for the right Drug

|
עמוד הבית / הומולין 70/30 / מידע מעלון לרופא

הומולין 70/30 HUMULIN 70/30 (INSULIN (HUMAN))

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תת-עורי : S.C

צורת מינון:

תרחיף להזרקה : SUSPENSION FOR INJECTION

Adverse reactions : תופעות לוואי

4.8     Undesirable effects

Hypoglycemia is the most frequent undesirable effect of insulin therapy that a patient with diabetes may suffer. Severe hypoglycemia may lead to loss of consciousness, and in extreme cases, death. No specific frequency for hypoglycemia is presented, since hypoglycemia is a result of both the insulin dose and other factors e.g. a patient`s level of diet and exercise.

Local allergy in patients is common (≥1/100 to < 1/10). Redness, swelling, and itching can occur at the site of insulin injection. This condition usually resolves in a few days to a few weeks. In some instances, local reactions may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.

Systemic allergy, which is very rare (< 1/10,000) but potentially more serious, is a generalized allergy to insulin. It may cause rash over the whole body, shortness of breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe cases of generalized allergy may be life-threatening. In the rare event of a severe allergy to Humulin, treatment is required immediately. A change of insulin or desensitization may be required.

Lipodystrophy at the injection site is uncommon (≥1/1,000 to < 1/100).

Skin and subcutaneous tissue disorders: Frequency “unknown”: Cutaneous amyloidosis 
Skin and subcutaneous tissue disorders:
Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (See section 4.4).

Cases of edema have been reported with insulin therapy, particularly if previous poor metabolic control is improved by intensified insulin therapy.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

ELI LILLY ISRAEL LTD, ISRAEL

רישום

057 95 26959 11

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

14.11.17 - עלון לרופא 25.11.20 - עלון לרופא

עלון מידע לצרכן

14.11.17 - עלון לצרכן אנגלית 25.11.20 - עלון לצרכן אנגלית 25.11.20 - עלון לצרכן עברית 14.11.17 - עלון לצרכן ערבית 25.11.20 - עלון לצרכן ערבית 25.06.12 - החמרה לעלון 19.06.16 - החמרה לעלון 27.04.17 - החמרה לעלון 02.11.20 - החמרה לעלון

לתרופה במאגר משרד הבריאות

הומולין 70/30

קישורים נוספים

RxList WebMD Drugs.com